At the time of writing, CytomX Therapeutics Inc [CTMX] stock is trading at $2.65, up 5.16%. An important factor to consider is whether the stock is rising or falling in short-term value. The CTMX shares have gain 24.41% over the last week, with a monthly amount glided 256.04%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CytomX Therapeutics Inc [NASDAQ: CTMX] stock has seen the most recent analyst activity on May 15, 2025, when H.C. Wainwright upgraded its rating to a Buy but kept the price target unchanged to $5 for it. On May 28, 2024, upgrade upgraded it’s rating to Overweight and revised its price target to $3.50 on the stock. Wedbush upgraded its rating to a Outperform but stick to its price target of $8 on May 09, 2024. Jefferies upgraded its rating to a Buy and raised its price target to $8 on May 06, 2024. JP Morgan upgraded its rating to Neutral for this stock on April 22, 2024. In a note dated November 14, 2022, BMO Capital Markets downgraded an Market Perform rating on this stock and revised its target price from $3 to $2.60.
For the past year, the stock price of CytomX Therapeutics Inc fluctuated between $0.40 and $2.64. Currently, Wall Street analysts expect the stock to reach $5.73 within the next 12 months. CytomX Therapeutics Inc [NASDAQ: CTMX] shares were valued at $2.65 at the most recent close of the market. An investor can expect a potential return of 116.23% based on the average CTMX price forecast.
Analyzing the CTMX fundamentals
According to CytomX Therapeutics Inc [NASDAQ:CTMX], the company’s sales were 147.56M for trailing twelve months, which represents an 22.80% jump. Gross Profit Margin for this corporation currently stands at 0.65% with Operating Profit Margin at 0.24%, Pretax Profit Margin comes in at 0.28%, and Net Profit Margin reading is 0.28%. To continue investigating profitability, this company’s Return on Assets is posted at 0.42, Equity is -5.53 and Total Capital is 0.74. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.33.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.50 points at the first support level, and at 2.34 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.76, and for the 2nd resistance point, it is at 2.86.
Ratios To Look Out For
It is important to note that CytomX Therapeutics Inc [NASDAQ:CTMX] has a current ratio of 1.73. On the other hand, the Quick Ratio is 1.73, and the Cash Ratio is 0.95. Considering the valuation of this stock, the price to sales ratio is 2.83, the price to book ratio is 8.53 and price to earnings (TTM) ratio is 5.34.
Transactions by insiders
Recent insider trading involved McCarthy Sean A., CEO, that happened on Mar 18 ’25 when 37656.0 shares were sold. Chief Financial Officer, Ogden Christopher completed a deal on Mar 18 ’25 to sell 8551.0 shares. Meanwhile, Chief Medical Officer Chu Yu-Waye sold 4025.0 shares on Mar 18 ’25.
